Mark Erlander, PhD | Chief Scientific Officer

Mark Erlander joined Trovagene in 2013 as Chief Scientific Officer.

Prior to joining Trovagene, Dr. Erlander served as Chief Scientific Officer at bioTheranostics, a bioMerieux company, which was previously AviaraDx and acquired by bioMerieux. As CSO, he led R&D, Medical & Scientific Affairs and clinical laboratory operations for the development of proprietary predictive tests in oncology for therapy decisions that are currently in ASCO and NCCN guidelines.

Prior to this, Dr. Erlander was a Group Leader, and subsequently, Research Fellow in drug discovery at Johnson & Johnson (R.W. Johnson Pharmaceutical Research Institute). At J&J, Dr. Erlander led both efforts in drug discovery and the use of genomic technologies to identify new drug targets. Previous to this, he was an Assistant Member/Professor at The Scripps Research Institute where he also received his post-doctoral training.

Dr. Erlander is an accomplished researcher in oncology diagnostics, therapeutics and genomic technologies with 41 issued U.S. patents and over 50 pending applications. He has co-authored over 90 scientific publications.

Dr. Erlander’s main interest is precision medicine in oncology by leveraging the intersection between targeted therapies and molecular diagnostics.

Dr. Erlander holds a BS degree in Biochemistry from the University of California, Davis; an MS degree in Biochemistry from Iowa State University; and a Ph.D. in Neuroscience from the University of California, Los Angeles.